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Abstract: Septicemia is frequently associated with serious complications and high mortality despite 
recent advances in treatment with antibacterial agents. Infectious organisms or their soluble products 
initiate septic shock through a complex cytokine cascade. Lipopolysaccharide (LPS) induced excessive 
production of inflammatory cytokines is regarded as a model of septic shock. Experiments of LPS-
induced excessive cytokine production were conducted in Balb/c mice for the investigation of the 
therapeutic potential of anti-TNF-α and anti-IL-6 monoclonal antibody treatments. LPS injection 
resulted in mortality with significant serum levels of TNF-α, IL-6, and IL-1β. Anti-IL-6 treatment 
significantly reduced animal mortality and inhibited serum levels of IL-6. Anti-TNF-α treatment did 
not affect serum IL-6 levels even though it significantly enhanced animal survival and inhibited TNF-α 
production. Moreover, anti-IL-6 treatment modestly reduced serum TNF-α level in comparison with 
control antibody treated group. These data suggest that TNF-α and IL-6 may play distinct protective 
roles in septic shock. 
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INTRODUCTION 
 
  Endotoxin-induced septic shock is a leading cause 
of morbidity and mortality among hospitalized patients, 
and there is limited treatment currently available 
despite numerous mechanistic studies of the disease in 
the last two decades
[1]. Gram-negative bacteria have 
been suggested to be a common cause of septic shock, 
and lipopolysaccharide (LPS), a major constituent of 
Gram-negative bacterial outer membrane, is believed to 
be one of the primary mediators of septic shock. LPS 
and other bacterial constituents interact with proteins 
such as plasma lipoproteins and LPS binding protein in 
the circulation resulting in complexes that have high 
affinity for the opsonic receptor CD14, which then 
signals through the toll-like receptor 4 (TLR-4)-MD2 
complex on monocyte/macrophages 
[2]. This interaction 
occurs on the surface of mononuclear cells and triggers 
the activation of monocyte/macrophages and a wide 
range of inflammatory responses including over 
production of proinflammatory cytokines such as tumor 
necrosis factor (TNF)-α, interleukin (IL)-6, and 
interleukin (IL)-1β 
[1, 2]; activation of the L-arginine-
nitric oxide (NO) pathway and formation of oxidative 
free radicals
[3]; activation of the coagulation cascade, 
fibrinolysis, production of lipid mediators, and 
complement pathway 
[4]. All these complications lead to 
the multiple organ injury that occurs during endotoxic 
shock.  
  IL-6 is a pleiotropic cytokine with a variety of 
biological effects acting through specific gp80 and 
gp130 membrane receptors that mediate intracellular 
signal transduction
[5]. TNF-α, interleukin (IL)-8, and 
neutrophil degranulation were not affected by 
elimination of IL-6 in endotoxemia model of 
chimpanzees 
[6]. On the contrary, serum IL-6 levels 
were influenced by TNF-α infusion in humans 
[7]. It has 
been well established that serum IL-6 levels are greatly 
increased in sepsis patients 
[8]. Anti-TNFα treatment 
affected the cytokine expression in the plasma and 
myocardium in mice exposed to LPS. However, if the 
elevated myocardial expression of IL-6 and JE was not 
successfully controlled, anti-TNFα therapy many not be 
effective in the treatment of endotoxin shock 
[2]. 
Overall, the outcomes from various experimental septic 
shock models are controversial, and the underlying 
mechanism remains unclear. Recent studies indicated 
that IL-6 induced high C5a receptor levels in solid 
organs of murine sepsis and anti-IL-6 treatment 
significantly reduced mortality 
[4, 9]. 
  The current studies were designed to investigate 
the therapeutic potential of anti-IL-6 monoclonal Am. J. Immunol., 3 (1) : 4-9, 2007 
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antibody treatments for LPS-induced excessive 
cytokine production in Balb/c mice. Our studies 
confirmed that anti-TNF-α treatment significantly 
enhanced animal survival and inhibited TNF-α 
production, but it did not significantly affect serum IL-6 
level. Our studies demonstrated that anti-IL-6 treatment 
significantly inhibited serum levels of IL-6 and 
modestly reduced TNF-α level and subsequent animal 
mortality. Our data suggest that anti-TNF-α and anti-
IL-6 may have therapeutic utility and suggest distinct 
roles for both cytokines in septic shock. 
 
MATERIALS AND METHODS 
 
Antibodies and reagents: Rat IgG control mAb was 
purchased from Jackson Immunoresearch (West Grove, 
PA). Rat anti-mouse TNF-α Ab (Lot# 4922) and Rat 
anti-mouse IL-6 Ab (Lot# 5282305) were made by 
Centocor Cell Biology Lab (Centocor, Radnor, PA). 
 
Animals and experimental protocol: Five to seven 
weeks old Balb/c mice were obtained from Charles 
River Laboratories (Wilminton, MA). On day 0, the 
study animals were randomly assigned to test groups or 
a control group (15 mice/group). Animals were 
administered an intraperitoneal injection of control 
article or different monoclonal antibody (mAb) 
injections and approximately 1 hour later received an 
intravenous injection of LPS to induce septic shock. All 
animals were assessed four times daily for morbidity 
for 26 hours post-LPS injection. Blood was collected at 
4 hours post-LPS injection.  
 
Cytokine analysis by luminex: A n a l y s i s  o f  s e r u m  
cytokine levels was performed by incubation of 25 µl of 
serum with immobilized bead bound antibodies in a 16-
plex (Linco Research Inc., St. Charles, MO) Luminex 
assay for quantitative determination of 16 cytokines 
according to the manufacturer’s recommendations. 
Briefly, samples were harvested 4 hours or 24 hours 
after LPS injection and incubated with immobilized 
antibodies overnight at 4˚C, washed and detected by 
incubation with biotinylated detection antibody and 
streptavidin-phycoerythrin. Samples were read on a 
Luminex 100 (Luminex Corporation, Austin, TX). Data 
were analyzed using nonlinear fit equation. 
 
Serum amyloid A (SAA) analysis by ELISA: Serum 
SAA levels were determined by ELISA (Biosource, 
Camarillo, CA) according to the manufacturer’s 
recommendations. Briefly, serum samples were 
harvested at 4 hours after LPS injection and diluted 
1:1000 in assay diluent and incubated with conjugated 
anti-mouse SAA. Substrate tetramethylbenzidine was 
added and samples were read at 450 nm and analyzed 
using 4 parameter fit to determine sample values. 
 
RNA isolation and detection of C5r mRNA by real 
time PCR analysis: Lung, heart, liver, and kidney from 
5 random animals of each group were harvested 4 hours 
after LPS injection. Total RNA was isolated from lung, 
heart, liver, and kidney tissues using the RNeasy Mini 
Kit (Qiagen Inc., Valencia, CA) according to the 
manufacturer’s recommendations. Quality and quantity 
of RNA were assessed by Bioanalyzer (Agilent 
Technologies, Palo Alto, CA). Reverse transcription 
was performed with 2 µg of RNA using Reverse 
Transription Reagent kit (Applied Biosystems, Foster 
City, CA) based on manufacturer’s recommendations.  
  Real time PCR analysis was performed with 40 ng 
cDNA template using C5r primer/probe and Master 
Mix (Applied Biosystems) in a total of 20 µl reaction 
on the 7900HT (Applied Biosystems) according to the 
manufacture’s recommendations. GAPDH expression 
was also analyzed as a housekeeping gene using 
GAPDH primer/probe (Applied Biosystems). Duplicate 
samples were assayed and C5r levels in all treatment 
groups were normalized against GAPDH to yield ∆Ct, 
and then further normalized against a normal tissue 
sample to yield ∆∆Ct. Fold change of gene expression 
was calculated with the formula: 2
-∆∆Ct. 
 
Statistical analysis: Animal survival was expressed in 
groups, various serum cytokines and fold changes of 
C5r gene expression among various groups were 
expressed as individual plot for each animal with 
relevant mean. Statistical significance was determined 
by two-tailed analysis of variance by standard t-test.  
 
 
RESULTS 
 
Animal survival: To determine the effect of anti-IL-6 
mAb treatment in septic shock, survival rates of 
animals that received anti-IL-6 mAb treatment was 
compared to animals that received normal rat IgG 
control mAb after LPS induction of septic shock. 
Figure 1 shows the percentage of animals that survived 
for at least 26 hours post-LPS injection in each group. 
There were no survivors in the group of animals, which 
received normal rat IgG, 24 hours after LPS injection 
(Fig. 1). There was no additional mortality among the 
animals in the anti-IL-6 and anti-TNFα treatment  Am. J. Immunol., 3 (1) : 4-9, 2007 
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Fig. 1: Anti-IL-6  significantly reduced LPS-induced 
mortality.  Number of survived animals after LPS 
injection was recorded at various time points and 
converted to percentage using total number of animals 
(15 mice) for each group. * indicates p<0.05 as 
compared to the rat IgG-treated group. 
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Fig. 2a:  Anti-TNF-α and anti-IL-6 inhibited TNF-α 
production. Serum samples were collected from 
different groups of animals as indicated 4 hours 
after LPS injection. Levels of TNF-α were 
determined by Luminex and expressed as means. 
The insert represents data from a separate study in 
which combination of anti-TNF-α and anti-IL-6 
mAbs was compared with single mAb treatments. 
Samples were collected and assayed as in Fig. 2a. * 
indicates p<0.05 as compared to the rat IgG-treated 
group. 
 
groups between 26-72 hours post-LPS injection (data 
not shown). Anti-IL-6 treatment significantly improved 
animal survival (Fig 1), and anti-TNF-α treatment also 
significantly reduced animal mortality as reported 
previously (data not shown). These results suggest that 
IL-6 and TNF-α play important roles in LPS-induced 
septic shock.  
Rat IgG Anti-TNFα Anti-IL-6
0
2500 
5000 
7500 
10000 
*
Treatments
I
L
-
6
 
(
p
g
/
m
l
)
 
Rat IgG
Anti-IL-6
+Anti-IL-6
α
Anti-TNF-
0
100
200
300
400
500
5000
10000
* *
I
L
-
6
 
(
p
g
/
m
l
)
 
Fig. 2b:   Anti-TNF-α and anti-IL-6 inhibited IL-6 
production. Serum samples were collected from 
different groups of animals as indicated 4 hours 
after LPS injection. Levels of IL-6 were determined 
by Luminex and expressed as means. The insert 
represents data from a separate study in which 
combination of anti-TNF-α and anti-IL-6 mAbs 
was compared with single mAb treatments. Samples 
were collected and assayed as in Fig. 2b. * indicates 
p<0.05 as compared to the rat IgG-treated group.   
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Fig. 2c:  Anti-TNF-α and anti-IL-6 inhibited IL-
1β production. Serum samples were collected from 
different treatment groups of animals as indicated 4 
hours after LPS injection. Levels of IL-1β were 
determined by Luminex and expressed as means. 
The insert represents data from a separate study in 
which combination of anti-TNF-α and anti-IL-6 
mAbs was compared with single mAb treatments. 
Samples were collected and assayed as in Fig. 2c. * 
indicates  p<0.05 as compared to the rat IgG and 
anti-IL-6 treated groups. Am. J. Immunol., 3 (1) : 4-9, 2007 
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Fig. 3: Anti-TNF-α and anti-IL-6 treatments reduced SAA 
production. Serum samples were collected from 
different groups of animals 4 hours after LPS 
injection.  Levels of SAA were determined by ELISA 
and expressed as means. * indicates p<0.05 as 
compared to the rat IgG treated group. 
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Fig. 4a:  Anti-TNF-α and anti-IL-6 reduced C5r expression 
in the lung. Lung tissues were harvested from 5 
random animals of different groups 4 hours after 
LPS injection. Levels of C5r expression in diseased 
tissues were determined by real time RT-PCR and 
compared to that of the normal tissues. * indicates 
p<0.05 as compared to the rat IgG and anti-TNFα 
treatment groups. 
 
Serum levels of TNF-α, IL-6, and IL-1β:   Serum 
levels of TNF-α and IL-6 were then measured to 
investigate the effectiveness of anti-TNF-α and anti-IL-
6 mAbs in vivo. Not surprisingly, LPS injection 
significantly increased serum TNF-α, IL-6, and IL-1β 
levels (Fig2a-c). Anti-TNF-α and anti-IL-6 treatments 
significantly inhibited serum TNF-α and IL-6 levels, 
respectively, at 4 hrs after LPS injection as compared to 
control Ab treatment group (Fig. 2a, 2b). In addition, 
anti-IL-6 treatment significantly inhibited serum and 
TNF-α level. In contrast, anti-TNF-α treatment did not 
affect serum IL-6 level. In a separate study where a 
sub-lethal   dose of LPS was used, the   combination  of  
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Fig. 4b:  Anti-TNF-α and anti-IL-6 reduced C5r expression 
in the heart. Heart samples were harvested from 4-5 
random animals of different groups 4 hours after 
LPS injection. Levels of C5r expression in diseased 
tissues were determined by real time RT-PCR and 
compared to that of the normal tissues. * indicates 
p<0.05 as compared to the rat IgG treatment group. 
 
anti-TNF-α and anti-IL-6 treatment significantly 
inhibited  serum  TNF-α  level that  was  comparable to  
that of anti-TNF-α treatment alone (Fig. 2a insert). In 
addition, the combination treatment showed similar 
inhibitory effects on serum IL-6, level as anti-IL-6 
treatment alone (Fig. 2b insert). The combination 
treatment significantly inhibited serum IL-1ß level as 
compared to rat IgG and anti-IL-6 treatment alone (Fig. 
2c).  
 
Serum amyloid A Levels.  
  The major acute-phase protein, serum amyloid A 
(SAA), is upregulated by a variety of inflammatory 
stimuli, including cytokines and glucocorticoids. 
Elevated systemic concentrations of SAA, IL-6, and 
TNF-α are features of an ongoing inflammatory 
response. Treatment with anti-TNF-α and anti-IL-6 
mAbs resulted in a decreased level of serum SAA (Fig. 
3) indicating the treatments inhibited the elevated 
inflammation induced by LPS.  
 
C5r expression in tissues: C5r expression has been 
shown to be associated with IL-6 level in various 
inflammatory tissues. C5r expression was examined in 
lung, heart, liver, and kidney 4 hours post-LPS 
administration. Anti-IL-6 treatment significantly 
inhibited C5r expression in the lung and heart (Fig. 4a 
and 4b), while neither anti-IL-6 nor anti-TNFα 
significantly affected C5r expression in the liver and 
kidney (data not shown). 
α 
α Am. J. Immunol., 3 (1) : 4-9, 2007 
 
  8
DISCUSSION 
  
  Leukocyte recruitment in various tissues and the 
subsequent dysregulation of proinflammatory responses 
contribute to the elevated levels of TNF-α, IL-6, and 
IL-1ß as well as mortality in septic shock. The 
suppression of these proflammatory cytokines with 
pharmacological strategies or genetic manipulation 
significantly dampens the hyperpathophysiological 
responses and protects animals from septic death 
[10]. In 
our present study, LPS injection induced significant 
production of TNF-α, IL-6, and IL-1ß, which was 
associated with high mortality in Balb/c mice. Anti-
TNF-α and anti-IL-6 mAb treatments significantly 
reduced LPS-induced mortality in these mice. Anti-IL-6 
treatment not only significantly reduced serum IL-6 
level, but also reduced serum TNF-α level in mice 
injected with LPS. Anti-TNF-α and anti-IL-6 may 
impact independent pathways in LPS-induced septic 
shock since neither synergistic nor additive effects were 
observed with combination treatment.  
  In addition to proinflammatory cytokines, recent 
studies suggested that complement C5 and its receptor 
C5r appeared to be associated with IL-6 in the 
inflammatory responses occurred in a mouse sepsis 
model 
[4, 9]. C5r was shown to be upregulated in various 
organs, such as heart, kidney, and liver, by the elevated 
level of IL-6. Anti-IL-6 mAb treatment significantly 
suppressed C5r expression and improved animal 
survival. In our study, anti-IL-6 mAb treatment 
significantly reduced C5r expression in the lung and 
heart tissues. Furthermore, a series of in vitro studies 
with endothelial cells demonstrated that C5 could 
induce significant activation of genes associated with 
inflammation, i.e. adhesion molecules, proinflammatory 
cytokines as well as chemokines 
[11]. Conversely, 
proinflammatory molecules, such as IL-6, could induce 
C5r expression in endothelial cells 
[12]. This elevated 
IL-6 level can subsequently sets off a vicious cycle 
since in vitro stimulation of human umbilical vein 
endothelial cells with human C5 resulted in progressive 
increases in gene expression of adhesion molecules and 
cytokines 
[11]. Mouse dermal microvascular endothelial 
cells cultured with IL-6 had increased C5 mRNA 
expression as well as protein expression on the cell 
surface 
[12]. In our study, anti-IL-6 mAb treatment 
significantly reduced serum TNF-α level while anti-
TNF-α mAb treatment did not affect serum IL-6 level 
in our study.  
 
 
 
  Combination treatment of anti-TNF-α and anti-IL-
6 did not further inhibit serum TNF-α and IL-6 levels 
as compared to anti-TNF-α treatment and anti-IL-6 
treatment alone, respectively. Only the combination 
treatment significantly inhibited serum IL-1β level as 
compared to rat IgG and anti-IL-6 treatment alone. 
These results suggest that TNF-α and IL-6 play distinct 
protective roles in septic shock. Not only did anti-IL-6 
mAb treatment directly suppress the elevated IL-6 level 
in septic shock, but the treatment also indirectly 
inhibited C5 and C5r levels, which resulted in lower 
overall inflammatory responses including TNF-α 
production. On the other hand, anti-TNF-α treatment 
only inhibited the elevated TNF-α level; it did not 
suppress the elevated C5r level in the lung. In 
conclusion, conventional approach using anti-
proinflammatory cytokine antibody may not be the best 
strategy for septic shock treatment. Our study along 
with other recent reports suggest that anti-
proinflammatory cytokine treatment that also inhibit 
complement activation results in higher animal survival 
and lower inflammation in mouse septic shock models. 
More studies are needed to fully clarify the 
mechanisms. 
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